Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24383281 | 0.98 | ALDH1A1 (0.44) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL25598334 | 0.94 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL20149856 | 0.93 | ALDH1A1 (0.45) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL24383374 | 0.91 | KMT2A (0.43) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL23373452 | 0.91 | ASAH1 (0.51) | ALDH1A1HPGDKMT2AMEN1HDAC6 | |
| SCHEMBL890354 | 0.90 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL8842993 | 0.90 | MMP2 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL14847398 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL16472145 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL25969983 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HPGDKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | ALDH1A1 3876/4885HPGD 4231/4885KMT2A 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.